» Articles » PMID: 24251151

Detecting Growth Hormone Misuse in Athletes

Overview
Specialty Endocrinology
Date 2013 Nov 20
PMID 24251151
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Athletes have been misusing growth hormone (GH) for its anabolic and metabolic effects since the early 1980s, at least a decade before endocrinologists began to treat adults with GH deficiency. Although there is an ongoing debate about whether GH is performance enhancing, recent studies suggest that GH improves strength and sprint capacity, particularly when combined with anabolic steroids. The detection of GH misuse is challenging because it is an endogenous hormone. Two approaches have been developed to detect GH misuse; the first is based on the measurement of pituitary GH isoforms and the ratio of 22-kDa isoform to total GH. The second is based on the measurement of insulin like growth factor-I (IGF-I) and N-terminal propeptide of type III procollagen (P-III-NP) which increase in a dose-dependent manner in response to GH administration. Both methodologies have been approved by the World Anti-Doping Agency (WADA) and have led to the detection of a number of athletes misusing GH.

Citing Articles

Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labelled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution/High-Accuracy Mass Spectrometry.

Krombholz S, Thomas A, Thevis M Metabolites. 2022; 12(2).

PMID: 35208220 PMC: 8877552. DOI: 10.3390/metabo12020146.


Coupling Complete Blood Count and Steroidomics to Track Low Doses Administration of Recombinant Growth Hormone: An Anti-Doping Perspective.

Narduzzi L, Buisson C, Morvan M, Marchand A, Audran M, Le Bouc Y Front Mol Biosci. 2021; 8:683675.

PMID: 34179089 PMC: 8222787. DOI: 10.3389/fmolb.2021.683675.


Obese adolescents exhibit a constant ratio of GH isoforms after whole body vibration and maximal voluntary contractions.

Rigamonti A, Haenelt M, Bidlingmaier M, De Col A, Tamini S, Tringali G BMC Endocr Disord. 2018; 18(1):96.

PMID: 30587244 PMC: 6307112. DOI: 10.1186/s12902-018-0323-6.


Sports Pharmacology: A Medical Pharmacologist's Perspective.

Malve H J Pharm Bioallied Sci. 2018; 10(3):126-136.

PMID: 30237683 PMC: 6142890. DOI: 10.4103/jpbs.JPBS_229_17.


The Use and Abuse of Human Growth Hormone in Sports.

Siebert D, Rao A Sports Health. 2018; 10(5):419-426.

PMID: 29932857 PMC: 6116101. DOI: 10.1177/1941738118782688.

References
1.
Healy M, Dall R, Gibney J, Bassett E, Ehrnborg C, Pentecost C . Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting. J Clin Endocrinol Metab. 2004; 90(2):641-9. DOI: 10.1210/jc.2004-0386. View

2.
Cuneo R, Salomon F, McGauley G, Sonksen P . The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 1992; 37(5):387-97. DOI: 10.1111/j.1365-2265.1992.tb02347.x. View

3.
Janssen Y, Doornbos J, Roelfsema F . Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab. 1999; 84(1):279-84. DOI: 10.1210/jcem.84.1.5411. View

4.
Irie M, Ueki M, Kishikawa Y, Nishii M, Kawahara T . 20K-GH and its use in detecting GH abuse. Growth Horm IGF Res. 2009; 19(4):352-6. DOI: 10.1016/j.ghir.2009.04.013. View

5.
Wu R, St Louis Y, DiMartino-Nardi J, Wesoly S, SOBEL E, Sherman B . Preservation of physiological growth hormone (GH) secretion in idiopathic short stature after recombinant GH therapy. J Clin Endocrinol Metab. 1990; 70(6):1612-5. DOI: 10.1210/jcem-70-6-1612. View